Abstract 1919P
Background
Around 10% of patients affected by pleural mesothelioma (PM) carry a germline pathogenic variant (PV). Some of these variants might be therapeutically exploited using targeted agents. The goal of this study is to clinically characterize the PM patients that carry germline mutations.
Methods
A blood sample was drawn and germline NGS testing was performed using panel testing, that included 96-107 genes involved in inherited cancer syndromes. Fifty-three of the analyzed genes were involved in DNA repair. The identified PVs were confirmed by Sanger sequencing [1-3]. The collection of extensive clinical data of the mutated patients is ongoing.
Results
Totally, 23/213 patients (10.8%) carried a germline PV. The most frequently mutated genes are BAP1 (6/23-26%), CDKN2A, SLX4 and BRCA1 (2/23 each, 8.6%), while 1 germline PV was found for ATM, BRCA2, BRIP1, CHEK2, FANCC, FANCF, FANCI, FLNC, PALB2, SBDS, VHL, XPC (1/23-4.3%). Twelve genes were involved in Homologous Recombination Repair.Of these mutations BRCA1 and BRCA2 germline PVs are an ESCAT tier IIIa (13% of the germline PV carriers, 1.4% overall) for Olaparib, while ATM mutations might be considered an ESCAT tier IV for tazemetostat. Histology is epithelioid in 150, biphasic in 34, sarcomatoid in 22, unknown in 2 and not available in 5 patients.
Conclusions
The identification of PM patients carrying germline PVs may enrich the therapeutic landscape for PM. Analyses on the associations of PV and clinical variables are ongoing, putting in context the hypothetic predictive value of these alterations on conventional treatments for PM.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
L. Cerbone: Non-Financial Interests, Personal, Other, Travel and accommodation: Pierre Fabre. F. Grosso: Financial Interests, Personal, Advisory Role: BMS, MSD, Pierre Fabre, PharmaMar, Novocure, Novartis; Financial Interests, Personal, Speaker’s Bureau: Novocure. All other authors have declared no conflicts of interest.
Resources from the same session
1525P - Nab-paclitaxel/gemcitabine with or without epigenetic targeting followed by consolidating immune targeting with durvalumab and lenalidomide in patients with advanced pancreatic ductal adenocarcinoma: Results from the SEPION/AIO-PAK-0118 phase I/II study
Presenter: Jens Siveke
Session: Poster session 18
1527P - GnP vs mFOLFIRINOX or S-IROX in metastatic pancreatic cancer: 1-year follow-up updated data from the GENERATE (JCOG1611)
Presenter: Satoshi Kobayashi
Session: Poster session 18
1528P - TCOG T5221 trial: A phase II randomized study of gemcitabine and nab-paclitaxel in combination with S- 1/LV (GASL) or oxaliplatin (GAP) as first-line treatment for metastatic pancreatic cancer
Presenter: Yung-yeh Su
Session: Poster session 18
1531TiP - TWINPEAK phase I/II study, PT886 a bispecific antibody targeting claudin 18.2 and CD47 in combination with chemotherapy and/or pembrolizumab in gastric/GEJ-carcinomas or PDAC
Presenter: Michael Overman
Session: Poster session 18
1532TiP - Zolbetuximab with gemcitabine + nab-paclitaxel (GN) in first-line treatment of Claudin 18.2–positive metastatic pancreatic cancer (mPC): Phase II, open-label, randomized study
Presenter: Wungki Park
Session: Poster session 18
1533TiP - A multicenter, open-label phase II study to evaluate the efficacy and safety of pimicotinib (CSF-1R inhibitor) in combination with chemotherapy with or without toripalimab in patients (pts) with advanced pancreatic ductal adenocarcinoma (aPDAC)
Presenter: Xiaofei Zhang
Session: Poster session 18